Skip to main content

Veru (NASDAQ: VERU) — Company Overview, News & Financial Data

Veru logo
VERU Veru
Veru primary media
Company profile

Veru

About

Explore United States companies

Veru (NASDAQ:VERU) focuses on developing novel medicines for the management of breast cancer and severe COVID-19. With a dedicated team working steadfastly, their projects range from early-stage research to late-stage clinical trials aimed at addressing unmet medical needs. Furthermore, Veru is traded on the NASDAQ under the symbol VERU. The company's objective is not only to advance the treatment options available for breast cancer and serious COVID-19 cases but also to enhance patient outcomes through innovative therapeutic solutions. Their commitment to research and development in these critical areas underscores their dedication to improving health and making a meaningful impact in the lives of patients worldwide.

Snapshot

Public USOwnership
1971Year founded
189Employees
Miami, United StatesHead office
Loading Map...
Global footprint

Operations

All Locations
Miami, US

Products and/or services of Veru

  • Development of VERU-111, an oral selective antitubulin agent targeting metastatic breast cancer and COVID-19 associated ARDS.
  • Commercialization of FC2 Female Condom, designed for dual protection against unwanted pregnancies and sexually transmitted infections.
  • Progression of Enobosarm, a novel oral androgen receptor targeting agent, for androgen receptor positive metastatic breast cancer.
  • Advancement of VERU-100, a peptide formulation for androgen deprivation therapy in advanced prostate cancer treatment.
  • Exploration of zuclomiphene citrate, aimed at treating hot flashes in men undergoing hormone therapy for prostate cancer.
  • Marketing of TADFIN, a combination therapy for benign prostatic hyperplasia and erectile dysfunction.

Veru executive team

  • Mitchell S. SteinerChairman, President & CEO
  • Harry D. FischVice Chairman & Chief Corporate Officer
  • K. Gary BarnetteChief Scientific Officer
  • Michele GrecoCFO & Chief Administrative Officer
  • Samuel FischExecutive Director of Investor Relations & Corporate Communications
  • Philip R. GreenbergExecutive VP, General Counsel & Secretary
  • Kevin J. GilbertExecutive Vice President of Corporate Development
  • Martin TaylerExecutive Vice President of FC2 Global Operations
  • Domingo RodriguezExecutive Vice President of Global Clinical Operations
  • Gary BirdExecutive Vice President of Quality & Regulatory Affairs